[Edaily Reporter Kwon Oh Seok ] FnGuide Inc.(064850)’s stock price is surging in early trading. It appears that buying interest is surging on the back of positive outlooks from the securities industry. According to MP Doctor on the 22nd, FnGuide Inc. is trading at 22,900 won as of 9:31 a.m., up 10.36% from the previous trading day. Earlier that day, EUGENE INVESTMENT & SECURITIES released a report on FnGuide Inc., analyzing that the company is expected to achieve record earnings due to the expansion of the ETF (exchange-traded fund) market. Park Jong-seon, an analyst at EUGENE INVESTMENT & SECURITIES, stated, “We project third-quarter estimated earnings (on a consolidated basis) to reach 15.8 billion won in revenue and 8.3 billion won in operating profit—representing year-over-year increases of 88.1% and 207.3%, respectively—which would not only set a new record for quarterly revenue but also mark the highest operating profit on record.” Explaining the rationale behind the earnings growth forecast, he emphasized, “We expect revenue from the index division to continue driving earnings growth. Although the total net asset value of domestic ETFs has recently declined slightly, it is expected to gradually increase, led by thematic ETF products,” adding, “The company will maintain its growth momentum as its market share expands.” He further noted, “Revenue in the financial information services division is also expected to rise due to factors such as growing international interest in Korean companies,” adding, “Along with this revenue growth, operating profit is projected to reach a record high (8.3 billion won in operating profit, with an OPM of 52.2%).”
A virtual creator that doesn’t require a human actor has emerged. There is no pre-written script, nor is there an operator manipulating it in real time. Artificial intelligence (AI) hosts the broadcas…
“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…
(Graphic: Generative AI)
During the first week of August (August 3–7), SK BIOPHARMACEUTICALS posted its best-ever quarterly earnings, driven by the growth of its new epilepsy drug “cenobamate.” Ad…